Trial Outcomes & Findings for Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa (NCT NCT02811432)

NCT ID: NCT02811432

Last Updated: 2026-01-08

Results Overview

early neonatal mortality at 7 days

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

2221 participants

Primary outcome timeframe

7 days

Results posted on

2026-01-08

Participant Flow

Participant milestones

Participant milestones
Measure
Intervention
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Overall Study
STARTED
1110
1111
Overall Study
COMPLETED
1083
1102
Overall Study
NOT COMPLETED
27
9

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Kangaroo Mother Care
n=1110 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: aiming for 18 hours per day)
Standard Care
n=1111 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Total
n=2221 Participants
Total of all reporting groups
Age, Categorical
<=18 years
1110 Participants
n=9 Participants
1111 Participants
n=6 Participants
2221 Participants
n=9 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Age, Categorical
>=65 years
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Age, Continuous
20.3 hours
STANDARD_DEVIATION 11.6 • n=9 Participants
21.5 hours
STANDARD_DEVIATION 11.5 • n=6 Participants
20.9 hours
STANDARD_DEVIATION 11.6 • n=9 Participants
Sex: Female, Male
Female
552 Participants
n=9 Participants
550 Participants
n=6 Participants
1102 Participants
n=9 Participants
Sex: Female, Male
Male
558 Participants
n=9 Participants
561 Participants
n=6 Participants
1119 Participants
n=9 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Race (NIH/OMB)
Asian
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Race (NIH/OMB)
Black or African American
1110 Participants
n=9 Participants
1111 Participants
n=6 Participants
2221 Participants
n=9 Participants
Race (NIH/OMB)
White
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9 Participants
0 Participants
n=6 Participants
0 Participants
n=9 Participants
Region of Enrollment
Uganda
1110 participants
n=9 Participants
1111 participants
n=6 Participants
2221 participants
n=9 Participants

PRIMARY outcome

Timeframe: 7 days

early neonatal mortality at 7 days

Outcome measures

Outcome measures
Measure
Intervention
n=1083 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1102 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Mortality Within 7 Days
81 Participants
83 Participants

SECONDARY outcome

Timeframe: 24 hours

Prevalence of hypothermia at 24 hours post-randomisation using axillary temperature was assessed using a digital thermometer.

Outcome measures

Outcome measures
Measure
Intervention
n=1096 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1101 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Prevalence of Hypothermia at 24 Hours Post-randomisation
448 participants
585 participants

SECONDARY outcome

Timeframe: 30 days

Time-to-stabilization was defined as the first time at which a neonate had met all of the following criteria for a continuous period of at least 24 hours: breathing spontaneously with SpO2 \>90% in room air; no need for supplemental oxygen or CPAP; respiratory rate 40-59 breaths per minute; no apneic episodes; heart rate 80-179 beats per minute; axillary temperature 36.0-37.4 °C; and no need for intravenous fluids.

Outcome measures

Outcome measures
Measure
Intervention
n=1081 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1100 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Time From Intervention/Control Procedures Starting to Clinical Stabilisation
5.1 days
Interval 4.1 to 6.7
4.9 days
Interval 3.8 to 6.5

SECONDARY outcome

Timeframe: 30 days

The date and time of death were prospectively recorded from the death certificate for in-hospital deaths. For deaths occurring after discharge, the date was recorded based on parent/caregiver verbal report. Median and IQR of time-to-event calculated as the 50th and 25th to 75th percentile of the distribution of event times among those who experienced the event.

Outcome measures

Outcome measures
Measure
Intervention
n=119 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=134 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Time From Starting Intervention/Control Procedures to Death
5.0 hours
Interval 2.5 to 10.7
5.9 hours
Interval 2.8 to 13.9

SECONDARY outcome

Timeframe: 30 days

Population: at the 28-30 day visit

The date and time of hospital admission and discharge were documented prospectively for the first admission episode.

Outcome measures

Outcome measures
Measure
Intervention
n=1083 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1102 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Mean Duration of Hospital Stay in Days
7.3 days
Standard Error 0.15
6.1 days
Standard Error 0.14

SECONDARY outcome

Timeframe: 30 days

Proportion of neonates who were exclusively breastmilk feeding at discharge, from the breast or by other means

Outcome measures

Outcome measures
Measure
Intervention
n=1083 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1102 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Proportion of Neonates Exclusively Breastmilk Feeding at Discharge
959 Participants
978 Participants

SECONDARY outcome

Timeframe: 28 days

All-cause mortality within 28 days. Vital status was documented at the 28-30-day follow-up visit. If participants did not attend, a telephone call was made the same day to ascertain outcome.

Outcome measures

Outcome measures
Measure
Intervention
n=1051 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1049 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Mortality Within 28 Days
119 Participants
134 Participants

SECONDARY outcome

Timeframe: 30 days

Population: by 28-30 day visit

Episodes in which a neonate was readmitted to the index hospital were prospectively recorded. Episodes in which a neonate was readmitted to a different hospital were recorded based on parent/caregiver verbal report.

Outcome measures

Outcome measures
Measure
Intervention
n=848 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=840 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Frequency of Readmission
0.02 readmission count
Standard Error 0.01
0.04 readmission count
Standard Error 0.01

SECONDARY outcome

Timeframe: 28 days

Population: by 28-30 day visit

Mean daily weight gain was calculated as the difference between weight at enrollment and 28-30-day follow-up, as measured by the study scale.

Outcome measures

Outcome measures
Measure
Intervention
n=761 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=731 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Daily Weight Gain at 28 Days
7.8 g/kg/day
Standard Error 0.3
7.1 g/kg/day
Standard Error 0.3

SECONDARY outcome

Timeframe: 28 days

Population: day 28-30 visit

The intention-to-treat analysis assessed the mean difference in Maternal Infant Responsiveness Instrument score between the two arms. Scores range from 0 to 110, with higher scores indicating greater attachment.

Outcome measures

Outcome measures
Measure
Intervention
n=758 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=725 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Infant-caregiver Attachment at 28 Days
85.4 MIRA score
Standard Error 0.28
85.0 MIRA score
Standard Error 0.28

SECONDARY outcome

Timeframe: 28 days

Population: at the 28-30 day visit

The intention-to-treat analysis assessed the mean difference in Women's Capabilities Index (WCI) score between the two arms. The WCI has a scale of 0 to 1, with higher scores indicating greater wellbeing. The analysis excluded duplicate entries for mothers of enrolled twins/triplets.

Outcome measures

Outcome measures
Measure
Intervention
n=624 Participants
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=602 Participants
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Women's Well-being at 28 Days
0.69 WCI score
Standard Error 0.01
0.68 WCI score
Standard Error 0.01

Adverse Events

Intervention

Serious events: 124 serious events
Other events: 180 other events
Deaths: 119 deaths

Control

Serious events: 125 serious events
Other events: 90 other events
Deaths: 134 deaths

Serious adverse events

Serious adverse events
Measure
Intervention
n=1051 participants at risk
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1049 participants at risk
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Blood and lymphatic system disorders
SAEs and other adverse events
0.76%
8/1051 • Number of events 8 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
0.95%
10/1049 • Number of events 10 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
Cardiac disorders
SAEs and other adverse events
0.00%
0/1051 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
0.10%
1/1049 • Number of events 1 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
Gastrointestinal disorders
SAEs and other adverse events
1.1%
12/1051 • Number of events 12 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
0.67%
7/1049 • Number of events 7 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
Respiratory, thoracic and mediastinal disorders
SAEs and other adverse events
5.6%
59/1051 • Number of events 59 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
6.0%
63/1049 • Number of events 63 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
Hepatobiliary disorders
Neonatal jaundice
0.38%
4/1051 • Number of events 4 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
0.57%
6/1049 • Number of events 6 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
Renal and urinary disorders
Acute kidney injury
0.10%
1/1051 • Number of events 1 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
0.00%
0/1049 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
Nervous system disorders
Neurological disorders
0.76%
8/1051 • Number of events 8 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
0.86%
9/1049 • Number of events 9 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
Infections and infestations
neonatal infections
3.2%
34/1051 • Number of events 34 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
3.3%
35/1049 • Number of events 35 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
General disorders
Hyperthermia
0.00%
0/1051 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
0.19%
2/1049 • Number of events 2 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.

Other adverse events

Other adverse events
Measure
Intervention
n=1051 participants at risk
Skin-to-skin care initiated as soon as possible following randomisation Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
Control
n=1049 participants at risk
Incubator or radiant warmer Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Hepatobiliary disorders
Neonatal jaundice
17.1%
180/1051 • Number of events 180 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
8.6%
90/1049 • Number of events 90 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.

Additional Information

Professor Joy Lawn

London Sch Hygiene & Trop Medicine -

Phone: +44 (0)20 7636 8636

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place